MDxHealth Suspends 2026 Revenue Guidance After Preliminary Q3 Revenue

04:39 PM EDT, 10/15/2026 (MT Newswires) -- MDxHealth S.A (MDXH) said Thursday it suspended its full-year 2026 revenue guidance after preliminary Q3 revenue fell short of expectations, citing unexpected turnover among sales staff following the discontinuation of its Resolve mdx business. The company expects Q3 revenue from continuing operations of about $22.7 million, unchanged from a year earlier, while cash and cash equivalents totaled about $31.7 million at Sept. 30, 2026. Chief Executive Michael K. McGarrity said the company is focused on fortifying affected sales territories and returning to consistent execution. MDxHealth plans to provide further details when it reports full Q3 results and hosts its earnings call on Nov. 12.